NCT01199731终止2 期
A Phase 2b Study to Select a Once Daily Oral Dose of GSK2248761 in HIV-1 Infected Antiretroviral Therapy Experienced Adults With Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) Resistance
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- Percentage of Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) <50 Copies Per Milliliter (/mL) at Week 16
研究概览
简要总结
This 48 week, phase 2b study in 150 HIV-1 infected antiretroviral therapy experienced adult subjects consists of a dose-ranging evaluation of GSK2248761 at blinded doses of 100 mg and 200 mg once daily with a control arm of open-label etravirine (ETV) 200 mg twice daily. The background ART for all three arms will be darunavir/ritonavir (DRV/r) 600 mg/100 mg twice daily plus raltegravir (RAL) 400 mg twice daily. Antiviral activity, safety, PK, and development of viral resistance will be evaluated.
详细描述
Study SGN113399 is a Phase 2b randomized, partially-blinded, multicenter, parallel-group, dose-ranging study to be conducted in HIV-1 infected ART-experienced adults with documented NNRTI resistance.
A minimum of 150 subjects will be randomized 1:1:1 to one of two GSK2248761 doses or a control regimen containing ETV (50 subjects per group); all subjects will also receive darunavir/ritonavir and raltegravir. The trial will be partially blinded, i.e. subjects receiving GSK2248761 and the investigators will be blinded to the dose they receive. Subjects will not be blinded to whether they receive GSK2248761 or ETV.
Randomization will be stratified by:
- HIV-1 VL at screening, <50,000 copies/mL or >/50,000 copies/mL, and
- Darunavir susceptibility (screening phenotype fold change <7 or >/7 to 20)
Background ART will be administered open-label.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •HIV-1 infected adults greater than or equal to 18 years of age. Females are eligible to enter and participate in the study if she is (1) non-childbearing potential, (2) child bearing potential with negative pregnancy test at screening and Day 1 and agrees to use protocol-specified methods of birth control while on study.
- •HIV-1 infection with a screening plasma HIV-1 RNA greater than or equal to 400copies/mL
- •Previously received or current treatment with antiretroviral therapy (HAART) for HIV-1 infection (patient may be off ART at time of screening)
- •HIV-1 harboring NNRTI resistance by screening genotype (defined as the presence of at least 1 NNRTI resistance-associated mutations)
排除标准
- •Any pre-existing physical or mental condition (including substance abuse disorder) which, in the opinion of the Investigator, may interfere with the subject's ability to comply with the dosing schedule and/or protocol evaluations or which may compromise the safety of the subject
- •Any condition which, in the opinion of the Investigator, may interfere with the absorption, distribution, metabolism or excretion of the drug or render the subject unable to take oral medication
- •Women who are currently breastfeeding
- •Any evidence of an active Centers for Disease and Prevention Control (CDC) Category C disease [CDC, 1993], except cutaneous Kaposi's sarcoma not requiring systemic therapy
- •History of ongoing or clinically relevant hepatitis within the previous 6 months, including chronic hepatitis B virus (HBV) infection (HBsAg positive). Asymptomatic individuals with chronic hepatitis C virus (HCV) infection will not be excluded, however Investigators must carefully assess if therapy specific for HCV infection is required; subjects who are anticipated to require such therapy during the randomized portion of the study must be excluded
- •History of liver cirrhosis with or without hepatitis viral co-infection
- •Ongoing or clinically relevant pancreatitis
- •History of the following cardiac diseases: myocardial infarction, congestive heart failure, documented hypertrophic cardiomyopathy, sustained ventricular tachycardia
- •Personal or known family history of prolonged QT syndrome
- •History or presence of allergy or intolerance to the study drugs or their components, or a history of drug or other allergy that, in the opinion of the Principal Investigator, contraindicates their participation. In addition, if heparin is used during PK sampling, subjects with a history of sensitivity to heparin or heparin-induced thrombocytopenia should not be enrolled
- •HIV-1 genotype results with any of the following will be excluded: (1)Any screening genotype with virus showing a Y181 mutation in combination with any other NNRTI resistance-associated mutations, (2) Any screening genotype with virus showing a Y181I or Y188L alone or in combination with any other NNRTI resistance-associated mutations
- •HIV-1 phenotype results with any of the following will be excluded: (1) Any screening phenotype with virus showing etravirine fold change >10, (2) Any screening phenotype with virus showing darunavir fold change > 20, (3) Any screening phenotype with virus showing raltegravir fold change >1.5
- •Any acute laboratory abnormality at screening, which, in the opinion of the Investigator, would preclude the subject's participation in the study of an investigational compound. Any verified Grade 4 laboratory abnormality at screening would exclude a subject from study participation unless the Investigator can provide a compelling explanation for the laboratory result(s) and has the assent of the medical monitor
- •Any of the following laboratory values at screening: (1) Creatinine clearance <50 mL/min via Cockroft-Gault method, (2) Alanine aminotransferase (ALT) greater than or equal to 5 times ULN. Subjects with ALT >2xULN but <5xULN may participate in the study, if in the opinion of the Investigator and GSK medical monitor the lab abnormality will not interfere with the study procedures or compromise subject safety, (3) Alanine aminotransferase (ALT) greater than or equal to 3xULN and bilirubin greater than or equal to 1.5xULN (with >35% direct bilirubin
- •Any clinically significant finding on screening electrocardiograph (ECG), specifically (a single repeat is allowed to determine eligibility): (1) Heart rate <45 and >100bpm (males), <50 and >100bpm (females); Note: A heart rate from 100 to 110 BPM can be rechecked within 30 minutes to verify eligibility, (2) QRS duration >120msec, (3) QTc interval >450msec, (4) Non-sustained (greater than or equal to 3 consecutive beats) or sustained ventricular tachycardia, (5) Sinus pauses >2.5 seconds, (6) 2nd degree (Type II) or higher AV (Atrioventricular) block, (7) Evidence of WPW (Wolff-Parkinson-White) syndrome (ventricular preexcitation), (8) Pathologic Q waves (defined as Q wave >40msec OR depth >0.4 mV, (9) Any other abnormality which in the opinion of the investigator would interfere with the safety of the subject
- •Treatment with any of the following agents within 28 days prior to screening, or has an anticipated need for these agents during the study: (1) radiation therapy or cytotoxic chemotherapeutic agents, (2) immunomodulators (such as systemic corticosteroids, interleukins, or interferons); Note: Subjects using short-term (<7 day) steroid tapers and inhaled corticosteroids are eligible for enrollment, (3) Any non-protocol-specified agent with documented activity against HIV-1 in vitro
- •Treatment with an HIV-1 immunotherapeutic vaccine within 90 days prior to screening
- •Receipt of an experimental drug and/or vaccine within 28 days or 5 half-lives, or twice the duration of the biological effect of the experimental drug or vaccine, whichever is longer, prior to screening
- •Immunization within 28 days prior to first dose of IP
研究组 & 干预措施
GSK2248761 100mg OAD
Experimental
In combination with darunavir/ritonavir BID and raltegravir BID
干预措施: GSK2248761 100 mg once daily (Drug)
GSK2248761 200mg OAD
Experimental
In combination with darunavir/ritonavir BID and raltegravir BID
干预措施: GSK2248761 200 mg once daily (Drug)
Etravirine
Active Comparator
In combination with darunavir/ritonavir BID and raltegravir BID
干预措施: Etravirine (Drug)
结局指标
主要结局
Percentage of Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) <50 Copies Per Milliliter (/mL) at Week 16
时间窗: At Week 16
Plasma for quantitative HIV-1 RNA was collected. The percentage of participants with HIV-1 RNA \<50 copies/mL at Week 16 has been presented. A 2 ml plasma was assayed with the real-time NucliSens EasyQ HIV-1 assay (bioMerieux) capable of quantifying as low as 2.5 c/mL by using three modifications to the standard assay: 15 microliters (µl) of extracted eluate, 20 µl of primer, and 5 µl of 2X enzyme in place of standard kit volumes. The validated assay incorporated molecular beacons for detection.
次要结局
- Change From Baseline in CD4+ Cell Counts Prior to Switch of GSK2248761(Baseline (Day 1) and Week 2, 4, 8, 12 and 16)
- Change From Baseline in CD4+ Cell Counts After Switch of GSK2248761(Baseline (Day 1) and post switch Week 1, 2, 4, withdrawal and Follow-up Week 4, 8, 12)
- Number of Participants Who Discontinued Treatment Due to AEs(Up to follow-up i.e. 2-4 weeks after the last study visit (due to early termination the last visit was on 19 July 2011))
- Number of Participants With Electrocardiograph (ECG) With Values of Potential Critical Concern (PCI)(Up to follow-up i.e. 2-4 weeks after the last study visit (due to early termination the last visit was on 19 July 2011))
- Number of Participants With Treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)(Up to follow-up i.e. 2-4 weeks after the last study visit (due to early termination the last visit was on 19 July 2011))
- Number of Participants With Abnormal Clinical Chemistry Laboratory Data With Grade 3 or 4 Treatment-Emergent (TE) Toxicities(Up to follow-up i.e. 2-4 weeks after the last study visit (due to early termination the last visit was on 19 July 2011))
- Number of Participants With Abnormal Hematology Laboratory Data With Grade 3 or 4 TE Toxicities(Up to follow-up i.e. 2-4 weeks after the last study visit (due to early termination the last visit was on 19 July 2011))
- Change From Baseline in Plasma HIV-1 RNA Prior to Switch of GSK2248761(Baseline (Day 1) and Week 2, 4, 8, 12 and 16)
- Change From Baseline in Plasma HIV-1 RNA After Switch of GSK2248761(Baseline (Day 1) and post switch Week 1, 2, 4, withdrawal and follow-up Week 4, 8, 12)
- Number of Participants Who Experienced Disease Progression (HIV-associated Conditions, AIDS and Death)(Up to follow-up i.e. 2-4 weeks after the last study visit (due to early termination the last visit was on 19 July 2011))
- Absolute Values of CD4+ Cell Counts After Switch of GSK2248761(Baseline (Day 1) and post switch Week 1, 2, 4, withdrawal and Follow-up Week 4, 8, 12)
研究者
研究点 (1)
Loading locations...
相似试验
终止
2 期
Dose-finding Study of GSK2248761 in Antiretroviral Therapy-Naive Subjects (SIGNET)Infection, Human Immunodeficiency VirusNCT01231555ViiV Healthcare23
已完成
2 期
A Dose Ranging Trial of GSK1349572 and 2 NRTI in HIV-1 Infected, Therapy Naive SubjectsInfection, Human Immunodeficiency VirusNCT00951015ViiV Healthcare208
已完成
2 期
Four-Drug Combination Treatment in Hiv-Infected Subjects Failing Therapy With Antiretroviral RegimensHIV InfectionsNCT00052117Pfizer300
进行中（未招募）
1 期
A Phase IIb study to select a once daily oral dose of GSK1349572 administered with either abacavir/lamivudine or tenofovir/emtricitabine in HIV-1 infected antiretroviral therapy naïve adult subjects.EUCTR2009-010269-21-FRGlaxoSmithKline Research and Development Ltd200
进行中（未招募）
不适用
A Phase IIb study to select a once daily oral dose of GSK1349572 administered with either abacavir/lamivudine or tenofovir/emtricitabine in HIV-1 infected antiretroviral therapy naïve adult subjects. - NDHIV-1 infected antiretroviral therapy naïve adult subjectsMedDRA version: 12.0Level: LLTClassification code 10064456Term: HIV infection WHO clinical stage IVEUCTR2009-010269-21-ITGlaxoSmithKline Research and Development Ltd200